DKA Medical Diagnosis: A Comprehensive Guide for Healthcare Professionals

Diabetic ketoacidosis (DKA) stands as a critical and life-threatening complication arising from diabetes, primarily observed in individuals with type 1 diabetes mellitus, although it can also manifest in those with type 2 diabetes. Characterized by a triad of uncontrolled hyperglycemia, metabolic acidosis, and elevated ketone body concentrations, prompt and accurate Dka Medical Diagnosis is paramount for effective management and improved patient outcomes. This article delves into the multifaceted aspects of DKA, providing an in-depth guide for healthcare professionals to enhance their understanding and clinical approach to this complex condition.

Etiology of Diabetic Ketoacidosis

DKA arises from a relative or absolute deficiency of insulin, compounded by an excess of counter-regulatory hormones such as glucagon, catecholamines, cortisol, and growth hormone. This hormonal imbalance triggers a cascade of metabolic derangements leading to the hallmark features of DKA. Several factors can precipitate DKA, broadly categorized as:

Insulin deficiency: This is the cornerstone of DKA pathophysiology. Inadequate insulin levels, whether due to missed doses, insulin pump failure, or new-onset type 1 diabetes, prevent glucose uptake by cells and promote unrestrained glucose production by the liver.
Increased counter-regulatory hormones: Stressful conditions like infections (pneumonia, urinary tract infections being common culprits), trauma, surgery, and acute illnesses elevate counter-regulatory hormones. These hormones exacerbate hyperglycemia by promoting gluconeogenesis and glycogenolysis and also stimulate lipolysis, contributing to ketogenesis.
Precipitating medical conditions: Beyond infections, various medical conditions can trigger DKA, including myocardial infarction, pulmonary embolism, pancreatitis, and stroke.
Medications: Certain drugs can disrupt glucose metabolism and precipitate DKA. Corticosteroids, thiazide diuretics, sympathomimetic agents, and pentamidine are known to elevate blood glucose. Notably, SGLT2 inhibitors, while beneficial for glycemic control, can paradoxically increase the risk of euglycemic DKA.
Substance abuse: Alcohol and cocaine abuse have been identified as risk factors for DKA, particularly recurrent episodes, often linked to medication non-adherence.
Non-compliance with insulin therapy: Especially prevalent in inner-city populations, poor adherence to insulin regimens due to socioeconomic factors, lack of education, or mental health issues is a significant cause of recurrent DKA.

Epidemiology of DKA

The incidence of DKA varies globally, ranging from 0 to 56 per 1000 person-years, influenced by geographic location and population characteristics. Key epidemiological trends include:

Prevalence: Higher among women and non-White populations.
Insulin Delivery Method: More frequent in patients using injectable insulin compared to subcutaneous insulin infusion pumps.
Age: Incidence in children varies widely across countries, with lower rates in developing nations and higher rates in developed countries like Sweden and Finland. Elderly populations are also at increased risk due to factors like insulin resistance and decreased thirst sensation.
Mortality: Mortality rates are generally low in developed countries (below 1%), but can exceed 5% in elderly patients and those with co-existing severe illnesses. Mortality is significantly influenced by factors such as age extremes, coma upon presentation, hypotension, and severe comorbidities.
Hospitalization trends: Data from the CDC’s United States Diabetes Surveillance System (USDSS) indicates a concerning rise in DKA hospitalization rates between 2009 and 2014, particularly among individuals under 45 years.

Despite declining overall mortality from hyperglycemic crises in the US, disparities persist, especially for Black men, highlighting the need for targeted interventions and improved access to care.

Pathophysiology of DKA: Unraveling the Metabolic Cascade

The pathophysiology of DKA is a complex interplay of hormonal imbalances and metabolic shifts. Insulin deficiency, coupled with elevated counter-regulatory hormones, sets off a series of events:

Hyperglycemia: Reduced glucose uptake by peripheral tissues and increased hepatic glucose production (gluconeogenesis and glycogenolysis) lead to a surge in blood glucose levels.
Ketonemia and Metabolic Acidosis: Insulin deficiency promotes lipolysis, releasing free fatty acids from adipose tissue. These fatty acids are transported to the liver and undergo β-oxidation, producing ketone bodies (β-hydroxybutyrate and acetoacetate). The accumulation of these acidic ketones overwhelms the body’s buffering capacity, resulting in metabolic acidosis.
Dehydration and Electrolyte Imbalance: Hyperglycemia induces osmotic diuresis, leading to significant fluid and electrolyte loss, particularly sodium, potassium, and phosphate. Vomiting, often associated with DKA, further exacerbates dehydration and electrolyte depletion. Despite serum potassium levels often appearing normal or even elevated initially due to extracellular shift, total body potassium is invariably depleted.
Hyperosmolarity: High blood glucose and sodium levels contribute to increased serum osmolality. Hyperosmolarity plays a crucial role in neurological symptoms, including altered mental status, observed in severe DKA.
Inflammatory Response: Emerging evidence suggests that hyperglycemia itself triggers a pro-inflammatory state, with increased levels of pro-inflammatory cytokines and markers of oxidative stress. This inflammatory cascade may contribute to some of the systemic complications of DKA.

Image alt text: Diagram illustrating the pathophysiology of Diabetic Ketoacidosis, highlighting the roles of insulin deficiency, increased counter-regulatory hormones, and their effects on glucose and fat metabolism leading to hyperglycemia, ketogenesis, and acidosis.

History and Physical Examination in DKA Medical Diagnosis

A thorough history and physical exam are critical first steps in dka medical diagnosis. Patients presenting with DKA may exhibit a spectrum of symptoms:

History:

Hyperglycemia symptoms: Polyuria, polydipsia, polyphagia, and unexplained weight loss are classic symptoms of hyperglycemia preceding DKA.
Dehydration symptoms: Decreased urine output, dry mouth, reduced sweating, and dizziness indicate volume depletion.
Gastrointestinal symptoms: Anorexia, nausea, vomiting, and abdominal pain are common, sometimes mimicking acute abdominal conditions.
Infection symptoms: Fever, cough, dysuria, or other signs of infection should be actively sought as infections are frequent DKA triggers.
Neurological symptoms: Headache, confusion, drowsiness, and altered mental status can occur, especially in severe DKA or with cerebral edema.
Medication and substance use history: Detailed medication history, including insulin regimen and adherence, and substance use (alcohol, drugs) are crucial for identifying precipitating factors.

Physical Examination:

Vital Signs: Tachycardia and tachypnea are typical. Hypotension indicates significant dehydration and a more severe presentation. Temperature may be elevated (infection) or low (hypothermia, severe sepsis). Kussmaul breathing (deep, labored respirations) is a characteristic sign of metabolic acidosis.
Breath Odor: A fruity odor on the breath, due to acetone, may be detectable.
Dehydration signs: Dry mucous membranes, poor skin turgor, and delayed capillary refill.
Abdominal Examination: Abdominal tenderness, although non-specific, may be present.
Neurological Examination: Assess mental status carefully. Altered mental status, drowsiness, and focal neurological deficits are concerning signs of cerebral edema and require urgent intervention.

Evaluation and DKA Medical Diagnosis Criteria

Definitive dka medical diagnosis relies on laboratory confirmation of the classic triad: hyperglycemia, metabolic acidosis, and ketonemia. The commonly accepted diagnostic criteria include:

Hyperglycemia: Blood glucose level greater than 250 mg/dL (13.9 mmol/L). Note that euglycemic DKA, though less common, can occur, particularly in SGLT2 inhibitor users, where glucose levels may be lower (<250 mg/dL) despite significant ketoacidosis.
Metabolic Acidosis:
- Arterial pH less than 7.3 (venous pH < 7.3 may also be used).
- Serum bicarbonate level less than 15 mEq/L.
- Elevated anion gap metabolic acidosis (anion gap > 12 mEq/L, typically > 14-15 mEq/L). The anion gap is calculated as: Anion Gap = [Sodium + Potassium] – [Chloride + Bicarbonate].
Ketonemia or Ketonuria: Presence of ketones in serum or urine. Serum ketone measurement, specifically β-hydroxybutyrate, is preferred as it’s more accurate and quantitative. Urine ketone tests primarily detect acetoacetate and may underestimate the severity of ketosis.

Additional Laboratory Findings in DKA:

Electrolyte abnormalities:
- Sodium: Serum sodium is often falsely low due to hyperglycemia (hyperglycemic hyponatremia). Corrected sodium should be calculated: Corrected Sodium = Measured Sodium + 1.6 * [(Glucose – 100) / 100].
- Potassium: Initial serum potassium may be normal or elevated, but total body potassium is depleted. Insulin therapy will drive potassium intracellularly, potentially causing rapid hypokalemia.
- Phosphate and Magnesium: Often low, requiring repletion.
Leukocytosis: Common, even in the absence of infection.
Elevated Amylase and Lipase: Serum pancreatic enzymes can be elevated in DKA, even without pancreatitis. Clinical correlation and imaging (CT scan) may be needed to differentiate from pancreatitis if abdominal pain is prominent.
Elevated Triglycerides and Cholesterol: Lipid derangements are common in DKA, typically resolving rapidly with insulin therapy.
Glycated Hemoglobin (A1C): Provides information about long-term glycemic control and helps differentiate new-onset diabetes from pre-existing diabetes.
ECG: To assess for ischemic changes and electrolyte imbalances (hyperkalemia/hypokalemia).
Other investigations: Depending on clinical suspicion, urine, sputum, and blood cultures, chest X-ray (to rule out pneumonia), serum lipase, and other tests may be indicated to identify precipitating factors or co-existing conditions.

Treatment and Management of DKA

The cornerstone of DKA management is a multi-pronged approach focusing on:

Fluid Resuscitation: Addressing dehydration is the initial priority. Isotonic crystalloids (0.9% normal saline) are the mainstay. Initial bolus of 15-20 mL/kg body weight over the first hour is generally recommended. Subsequent fluid rate and type (0.45% NaCl or 0.9% NaCl) are guided by corrected serum sodium levels, hydration status, and urine output.
Insulin Therapy: Intravenous continuous insulin infusion is the standard of care. A bolus dose may not be necessary if starting with an infusion rate of 0.14 U/kg/hr. When blood glucose reaches 200-250 mg/dL, dextrose-containing fluids (D5W or D5NS) should be added, and the insulin infusion rate reduced to prevent hypoglycemia while continuing to resolve ketoacidosis. Subcutaneous rapid-acting insulin analogs (lispro, aspart) may be considered for mild to moderate DKA in non-ICU settings in stable adults.
Electrolyte Replacement:
- Potassium: Potassium replacement is almost always necessary. Initiate replacement when serum potassium is < 5.2 mEq/L, aiming to maintain levels between 4-5 mEq/L. In severe hypokalemia (<3.3 mEq/L), delay insulin and prioritize potassium replacement to avoid cardiac arrhythmias.
- Magnesium and Phosphate: Replete if levels are low, particularly if hypokalemia is refractory to potassium replacement alone.
- Bicarbonate: Generally not routinely recommended, and may be harmful. Consider only in severe acidemia (pH < 7.1) as per ADA guidelines, and with caution due to potential risks.
Monitoring:
- Hourly point-of-care glucose monitoring.
- Serum electrolytes, glucose, BUN, venous or arterial blood gas monitoring every 2-4 hours initially, then less frequently as the patient stabilizes.
- Continuous cardiac monitoring, especially during initial potassium replacement.
- Close neurological monitoring for signs of cerebral edema.
Identify and Treat Precipitating Factors: Thoroughly investigate and treat underlying infections or other medical conditions that triggered DKA.
Transition to Subcutaneous Insulin: Once DKA resolves (blood glucose < 200 mg/dL and at least two of the following: bicarbonate ≥ 15 mEq/L, venous pH > 7.3, anion gap ≤ 12 mEq/L) and the patient can tolerate oral intake, transition to subcutaneous insulin. Continue IV insulin for 1-2 hours after the first subcutaneous injection to prevent rebound hyperglycemia/ketosis.
Cerebral Edema Management: If suspected (altered mental status, neurological decline, papilledema – though rare in adults), immediate treatment is crucial. Mannitol and hypertonic saline (3%) are first-line agents.
Intubation Considerations: Avoid intubation if possible due to risks of worsening acidosis and aspiration. If necessary (severe respiratory distress or inability to protect airway), meticulous ventilator management is crucial to maintain compensatory respiratory alkalosis and prevent further pH drop.

Image alt text: Flowchart depicting a Diabetic Ketoacidosis (DKA) treatment algorithm, outlining steps for fluid resuscitation, insulin administration, electrolyte management, and monitoring parameters for effective patient care.

Differential Diagnosis of DKA

In dka medical diagnosis, it is crucial to consider other conditions that may mimic DKA, including:

Hyperosmolar Hyperglycemic State (HHS): Another hyperglycemic emergency in diabetes, but with more profound hyperosmolarity and less prominent ketosis and acidosis than DKA.
Alcoholic Ketoacidosis: Occurs in chronic alcohol abusers, characterized by ketosis and acidosis, but often with hypoglycemia or mild hyperglycemia. History is key for differentiation.
Starvation Ketosis: Mild ketosis due to prolonged fasting or very low carbohydrate diets. Glucose levels are usually low or normal, and acidosis is mild.
Lactic Acidosis: Elevated lactate levels causing metabolic acidosis. Various causes, including sepsis, shock, and metformin toxicity.
Toxic Ingestions: Ethylene glycol, methanol, paraldehyde, and salicylate poisoning can cause high anion gap metabolic acidosis. History and toxicology screening are important.
Sepsis: Can present with metabolic acidosis and altered mental status, but typically without significant hyperglycemia or ketosis unless in a diabetic patient.
Pancreatitis: Can cause abdominal pain and elevated amylase/lipase, potentially mimicking abdominal pain in DKA.
Myocardial Infarction: Chest pain can sometimes be misinterpreted as abdominal pain, and DKA can be precipitated by MI. ECG and cardiac enzymes are essential.
Diabetic Medication Overdose (e.g., Sulfonylureas): Can cause hypoglycemia and, less commonly, ketoacidosis in specific scenarios.
Uremia: Renal failure can cause metabolic acidosis, but not typically associated with significant hyperglycemia and ketosis unless in a diabetic patient with DKA.

Prognosis and Complications of DKA

With prompt diagnosis and appropriate management, the prognosis for DKA is generally good in developed countries, with mortality rates below 1%. However, certain factors worsen prognosis:

Coma on presentation.
Hypothermia.
Oliguria.
Advanced age.
Severe co-morbidities.
Cerebral edema (especially in children and young adults).

Complications of DKA and its treatment include:

Hypoglycemia: A common complication during treatment, requiring careful glucose monitoring and insulin dose adjustments.
Hypokalemia: Potentially life-threatening, necessitating proactive potassium replacement.
Cerebral edema: The most serious complication, particularly in children, but can occur in adults. Rapid neurological deterioration, headache, and altered mental status should prompt immediate evaluation and treatment.
Electrolyte disturbances: Hyperchloremia, hypomagnesemia, hypophosphatemia, and hyponatremia.
Rhabdomyolysis: More common in HHS but can occur in DKA, especially with severe hypophosphatemia.
Acute Respiratory Failure: Due to pneumonia, ARDS, or pulmonary edema (both cardiogenic and non-cardiogenic).
Thrombotic Thrombocytopenic Purpura (TTP) and Myocarditis: Rare but reported complications.
Renal Dysfunction: DKA can worsen pre-existing renal disease or, in some cases, lead to acute kidney injury.

Deterrence and Patient Education

Preventing DKA requires comprehensive diabetes education focusing on:

Disease process: Understanding diabetes and its complications, including DKA.
Glucose monitoring: Proper technique and frequency of blood glucose monitoring, and interpretation of results.
Medication management: Correct insulin administration (or oral hypoglycemic agents), importance of adherence, and recognizing signs of medication errors or pump malfunctions.
Sick-day management: Strategies to manage diabetes during illness, including increased glucose monitoring, adjusting insulin doses (often increasing), and when to seek medical attention.
Ketone monitoring: Educating patients on when and how to check urine or blood ketones, especially during illness or hyperglycemia.
Lifestyle modifications: Diet, exercise, and weight management.

Enhancing Healthcare Team Outcomes for DKA Management

Optimal DKA management necessitates a collaborative interprofessional team approach:

Emergency Department Team: Triage nurses must promptly recognize DKA symptoms and initiate immediate assessment and resuscitation. ED physicians lead initial stabilization and diagnosis.
Intensivists and Endocrinologists: Consultation is crucial for complex cases and ongoing management, particularly in the ICU setting.
Nurses: Vital for continuous monitoring, medication administration, electrolyte replacement, and patient education.
Pharmacists: Medication reconciliation, insulin dosage adjustments, electrolyte management guidance.
Radiologists: For timely interpretation of imaging studies (chest X-ray, CT scans).
Infectious Disease and Cardiology Specialists: Consultation as needed to address precipitating infections or cardiac events.
Social Workers: Essential for discharge planning, addressing socioeconomic barriers to medication adherence, and arranging follow-up care to prevent DKA recurrence.

By fostering effective communication and collaboration within the interprofessional team and prioritizing patient education, healthcare systems can significantly improve outcomes and reduce the burden of DKA.

Review Questions (Based on Original Article – For Self-Assessment)

(Please refer to the original article for multiple-choice questions and answers for self-assessment and continuing education credits.)

References

(References are listed as in the original article for academic integrity and further reading.)

Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009 Jul;32(7):1335-43.
Taylor SI, Blau JE, Rother KI. SGLT2 Inhibitors May Predispose to Ketoacidosis. J Clin Endocrinol Metab. 2015 Aug;100(8):2849-52.
Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J. Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma. Endocrinol Diabetes Metab Case Rep. 2017;2017
Gosmanov AR, Kitabchi AE. Diabetic Ketoacidosis. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. MDText.com, Inc.; South Dartmouth (MA): Apr 28, 2018.
Fazeli Farsani S, Brodovicz K, Soleymanlou N, Marquard J, Wissinger E, Maiese BA. Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review. BMJ Open. 2017 Aug 01;7(7):e016587.
Große J, Hornstein H, Manuwald U, Kugler J, Glauche I, Rothe U. Incidence of Diabetic Ketoacidosis of New-Onset Type 1 Diabetes in Children and Adolescents in Different Countries Correlates with Human Development Index (HDI): An Updated Systematic Review, Meta-Analysis, and Meta-Regression. Horm Metab Res. 2018 Mar;50(3):209-222.
Wachtel TJ, Tetu-Mouradjian LM, Goldman DL, Ellis SE, O’Sullivan PS. Hyperosmolarity and acidosis in diabetes mellitus: a three-year experience in Rhode Island. J Gen Intern Med. 1991 Nov-Dec;6(6):495-502.
Umpierrez GE, Kelly JP, Navarrete JE, Casals MM, Kitabchi AE. Hyperglycemic crises in urban blacks. Arch Intern Med. 1997 Mar 24;157(6):669-75.
Benoit SR, Zhang Y, Geiss LS, Gregg EW, Albright A. Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality – United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2018 Mar 30;67(12):362-365.
Wang J, Williams DE, Narayan KM, Geiss LS. Declining death rates from hyperglycemic crisis among adults with diabetes, U.S., 1985-2002. Diabetes Care. 2006 Sep;29(9):2018-22.
Gaglia JL, Wyckoff J, Abrahamson MJ. Acute hyperglycemic crisis in the elderly. Med Clin North Am. 2004 Jul;88(4):1063-84, xii.
Philippe J. Insulin regulation of the glucagon gene is mediated by an insulin-responsive DNA element. Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7224-7.
Barnes AJ, Bloom SR, Goerge K, Alberti GM, Smythe P, Alford FP, Chisholm DJ. Ketoacidosis in pancreatectomized man. N Engl J Med. 1977 Jun 02;296(22):1250-3.
Fulop M, Tannenbaum H, Dreyer N. Ketotic hyperosmolar coma. Lancet. 1973 Sep 22;2(7830):635-9.
Umpierrez G, Freire AX. Abdominal pain in patients with hyperglycemic crises. J Crit Care. 2002 Mar;17(1):63-7.
Lorber D. Nonketotic hypertonicity in diabetes mellitus. Med Clin North Am. 1995 Jan;79(1):39-52.
Umpierrez GE, Khajavi M, Kitabchi AE. Review: diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Am J Med Sci. 1996 May;311(5):225-33.
Paulson WD, Gadallah MF. Diagnosis of mixed acid-base disorders in diabetic ketoacidosis. Am J Med Sci. 1993 Nov;306(5):295-300.
Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, Wall BM. Management of hyperglycemic crises in patients with diabetes. Diabetes Care. 2001 Jan;24(1):131-53.
Molitch ME, Rodman E, Hirsch CA, Dubinsky E. Spurious serum creatinine elevations in ketoacidosis. Ann Intern Med. 1980 Aug;93(2):280-1.
Warshaw AL, Feller ER, Lee KH. On the cause of raised serum-amylase in diabetic ketoacidosis. Lancet. 1977 Apr 30;1(8018):929-31.
Vantyghem MC, Haye S, Balduyck M, Hober C, Degand PM, Lefebvre J. Changes in serum amylase, lipase and leukocyte elastase during diabetic ketoacidosis and poorly controlled diabetes. Acta Diabetol. 1999 Jun;36(1-2):39-44.
Weidman SW, Ragland JB, Fisher JN, Kitabchi AE, Sabesin SM. Effects of insulin on plasma lipoproteins in diabetic ketoacidosis: evidence for a change in high density lipoprotein composition during treatment. J Lipid Res. 1982 Jan;23(1):171-82.
Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD000567.
Mahler SA, Conrad SA, Wang H, Arnold TC. Resuscitation with balanced electrolyte solution prevents hyperchloremic metabolic acidosis in patients with diabetic ketoacidosis. Am J Emerg Med. 2011 Jul;29(6):670-4.
Chua HR, Venkatesh B, Stachowski E, Schneider AG, Perkins K, Ladanyi S, Kruger P, Bellomo R. Plasma-Lyte 148 vs 0.9% saline for fluid resuscitation in diabetic ketoacidosis. J Crit Care. 2012 Apr;27(2):138-45.
Van Zyl DG, Rheeder P, Delport E. Fluid management in diabetic-acidosis–Ringer’s lactate versus normal saline: a randomized controlled trial. QJM. 2012 Apr;105(4):337-43.
Adrogué HJ, Barrero J, Eknoyan G. Salutary effects of modest fluid replacement in the treatment of adults with diabetic ketoacidosis. Use in patients without extreme volume deficit. JAMA. 1989 Oct 20;262(15):2108-13.
Edge JA, Jakes RW, Roy Y, Hawkins M, Winter D, Ford-Adams ME, Murphy NP, Bergomi A, Widmer B, Dunger DB. The UK case-control study of cerebral oedema complicating diabetic ketoacidosis in children. Diabetologia. 2006 Sep;49(9):2002-9.
Gosmanov AR, Gosmanova EO, Kitabchi AE. Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. MDText.com, Inc.; South Dartmouth (MA): May 9, 2021.
Kitabchi AE, Murphy MB, Spencer J, Matteri R, Karas J. Is a priming dose of insulin necessary in a low-dose insulin protocol for the treatment of diabetic ketoacidosis? Diabetes Care. 2008 Nov;31(11):2081-5.
Umpierrez GE, Latif K, Stoever J, Cuervo R, Park L, Freire AX, E Kitabchi A. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. Am J Med. 2004 Sep 01;117(5):291-6.
Razavi Z, Maher S, Fredmal J. Comparison of subcutaneous insulin aspart and intravenous regular insulin for the treatment of mild and moderate diabetic ketoacidosis in pediatric patients. Endocrine. 2018 Aug;61(2):267-274.
Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: An update of its etiology, pathogenesis and management. Metabolism. 2016 Apr;65(4):507-21.
Pasquel FJ, Umpierrez GE. Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment. Diabetes Care. 2014 Nov;37(11):3124-31.
Herpes virus fingerprinting. Lancet. 1979 Feb 03;1(8110):251-2.
Fayfman M, Pasquel FJ, Umpierrez GE. Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Med Clin North Am. 2017 May;101(3):587-606.
Duhon B, Attridge RL, Franco-Martinez AC, Maxwell PR, Hughes DW. Intravenous sodium bicarbonate therapy in severely acidotic diabetic ketoacidosis. Ann Pharmacother. 2013 Jul-Aug;47(7-8):970-5.
Glaser N, Barnett P, McCaslin I, Nelson D, Trainor J, Louie J, Kaufman F, Quayle K, Roback M, Malley R, Kuppermann N., Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. N Engl J Med. 2001 Jan 25;344(4):264-9.
Osuka A, Matsuoka T, Idoguchi K. Is this the worst outcome of metabolic syndrome? Hypophosphatemia and resulting cardiac arrest during the treatment of diabetic ketoacidosis with hypertriglyceridemia. Intern Med. 2009;48(16):1391-5.
Regmi A, Konstantinov NK, Agaba EI, Rohrscheib M, Dorin RI, Tzamaloukas AH. Respiratory Failure in the Course of Treatment of Diabetic Ketoacidosis. Clin Diabetes. 2014 Jan;32(1):28-31.
Abbas Q, Arbab S, Haque AU, Humayun KN. Spectrum of complications of severe DKA in children in pediatric Intensive Care Unit. Pak J Med Sci. 2018 Jan-Feb;34(1):106-109.
Kutlu AO, Kara C, Cetinkaya S. Rhabdomyolysis without detectable myoglobulinuria due to severe hypophosphatemia in diabetic ketoacidosis. Pediatr Emerg Care. 2011 Jun;27(6):537-8.
Konstantinov NK, Rohrscheib M, Agaba EI, Dorin RI, Murata GH, Tzamaloukas AH. Respiratory failure in diabetic ketoacidosis. World J Diabetes. 2015 Jul 25;6(8):1009-23.

Disclosures:

Jenna Lizzo declares no relevant financial relationships with ineligible companies.
Amandeep Goyal declares no relevant financial relationships with ineligible companies.
Vikas Gupta declares no relevant financial relationships with ineligible companies.